The University of Cambridge in the UK recently issued a communiqué saying that the university's team used artificial intelligence to design a novel broad-spectrum avian influenza vaccine, which showed protective efficacy against various variants of the avian influenza virus in animal experiments. The vaccine candidate was jointly developed by Cambridge University and its derivatives. Researchers collected avian influenza virus gene sequence data recorded by global monitoring projects, integrated analysis using AI tools, and designed a series of “superantigens” containing common antigenic characteristics of such viruses. Antigens are components in vaccines that can trigger the body's immune response. After screening through cell tests, the team used the selected antigens for the vaccine and conducted animal experiments.

The University of Cambridge in the UK recently issued a communiqué saying that the university's team used artificial intelligence to design a novel broad-spectrum avian influenza vaccine, which showed protective efficacy against various variants of the avian influenza virus in animal experiments. The vaccine candidate was jointly developed by Cambridge University and its derivatives. Researchers collected avian influenza virus gene sequence data recorded by global surveillance projects, integrated analysis using AI tools, and designed a series of “superantigens” containing common antigenic characteristics of such viruses. Antigens are components in vaccines that can trigger the body's immune response. After screening through cell tests, the team used the selected antigens for the vaccine and conducted animal experiments.